Antibiotic resistance problems with Helicobacter pylori

International Journal of Antimicrobial Agents

Volumn 12, Issue 1, 1999, Pages 19-26

  Alarcón, Teresa ^a   Domingo, Diego ^a   López Brea, Manuel ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Clarithromycin; Helicobacter pylori; Metronidazole; Resistance; Susceptibility methods

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; BISMUTH SALICYLATE; BISMUTH SALT; CLARITHROMYCIN; FURAZOLIDONE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; MACROLIDE; METRONIDAZOLE; NALIDIXIC ACID; OMEPRAZOLE; PANTOPRAZOLE; POLYMYXIN DERIVATIVE; PROTON PUMP INHIBITOR; RANITIDINE BISMUTH CITRATE; SULFONAMIDE; TETRACYCLINE; TRIMETHOPRIM; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL GENE; GENE MUTATION; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS;

EID: 0033012877     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(99)00051-5     Document Type: Review

References (93)

1. Dunn B.E., Cohen H., Blaser M.J. Helicobacter pylori. Clin. Microbiol. Rev. 10:1997;720-741.
2. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in peptic ulcer disease. J. Am. Med. Assoc. 272:1994;65-69.
3. Parsonnet J., Friedman G.D., Vandersteen D.P. et al. Helicobacter pylori infection and the risk of gastric carcinoma. New Engl. J. Med. 325:1991;1127-1131.
4. World Health Organization: IARC monographs on the evaluation of carcinogenic risks to human, vol. 61. Geneva: World Health Organization, 1994:177-240.
5. Wotherspoon A.C., Ortiz-Hidalgo C., Falzon M.R., Isaacson P.G. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet. 338:1991;1175-1176.
6. Patel P., Gasbarrini G., Pretolani S., Gasbarrini A., Franceschi F. Extradigestives diseases and Helicobacter pylori infection. Curr. Opin. Gastroenterol. 13:1997;52-55.
7. Marshall B.J., Warren J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. i:1984;1311-1315.
8. Xia H.X., Talley N.J. Prospects for improved therapy for Helicobacter pylori infection. Exp. Opin. Invest. Drugs. 5:1996;959-976.
9. Alarcón T., Domingo D., Sánchez I., Diaz de Rojas F., López-Brea M. In vitro activity of omeprazole in combination with several antimicrobial agents against clinical isolates of Helicobacter pylori. Eur. J. Clin. Microbiol. Infect. Dis. 15:1996;937-940.
10. López-Brea M., Domingo D., Sánchez I., Prieto N., Alarcón T. Study of the combination of ranitidine bismuth citrate and metronidazole against metronidazole resistant H. pylori clinical isolates. J. Antimicrob. Chemother. 42:1998;309-314.
11. Midolo P.D., Turnidge J.D., Lambert J.R. Bactericidal activity and synergy studies of proton pump inhibitors and antibiotics against Helicobacter pylori in vitro. J. Antimicrob. Chemother. 39:1997;331-337.
12. Malizia T., Tejada M., Marchetti F. et al. Synergic interactions of macrolides and proton pump inhibitors against Helicobacter pylori: a comparative in vitro study. J. Antimicrob. Chemother. 41(suppl. B):1998;29-35.
13. Meyer J.M., Ryu S., Pendland S.L., Danziger L.H. In vitro synergy testing of clarithromycin and 14-Hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori. Antimicrob. Agents Chemother. 41:1997;1607-1608.
14. Buckley M.J.M., Deltenre M. Therapy of Helicobacter pylori infection. Curr. Opin. Gastroenterol. 13:1997;56-62.
15. Unge P., Berstad A. Pooled analysis of anti-Helicobacter pylori treatment regimens. Scand. J. Gastroenterol. 220(suppl.):1996;27-40.
16. Van der Hulst R.W., Keller J.J., Rauws E.A., Tytgat G.N. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter. 1:1996;6-19.
17. Megraud F. Resistance of Helicobacter pylori to antibiotics. Aliment. Pharmacol. Ther. 11(suppl. 1):1997;43-53.
18. Alarcón T., Domingo D., López-Brea M. Discrepancies between E-test and agar dilution methods for testing metronidazole susceptibility of Helicobacter pylori. J. Clin. Microbiol. 36:1998;1165-1166.
19. Glupczynski Y., Labbé M., Hansen W., Crokaert F., Yourassowsky E. Evaluation of the E-test for quantitative antimicrobial susceptibility testing of Helicobacter pylori. J. Clin. Microbiol. 29:1991;2072-2075.
20. Hirschl A.M., Hirschl M.M., Rotter M.L. Comparison of three methods for the determination of the sensitivity of H. pylori to metronidazole. J. Antimicrob. Chemother. 32:1993;45-49.
21. Von Recklinghausen G., Ansorg R. Metronidazole susceptibility testing of Helicobacter pylori with the PDM epsilometer test (E-test). Int. J. Med. Microbiol. Virol. Parasitol. Infect. Dis. 282:1995;83-85.
22. Piccolomini R., Di Bonaventura G., Catamo G., Carbone F., Neri M. Comparative evaluation of the E-test, agar dilution and broth microdilution for testing susceptibilities of Helicobacter pylori strains to 20 antimicrobial agents. J. Clin. Microbiol. 35:1997;1842-1846.
23. Hachem C.Y., Clarridge J.E., Reddy R. et al. Antimicrobial susceptibility testing of Helicobacter pylori. Comparison of E-test, broth microdilution and disk diffusion for ampicillin, clarithromycin and metronidazole. Diagn. Microbiol. Infect. Dis. 24:1996;37-41.
24. Glupczynski Y., Andersen L.P., Lopez-Brea M., Megraud F. Toward standarisation of antimicrobial susceptibility testing of H. pylori: preliminary results by a European multicentre study group. Gut. 43(suppl. 2):1998;47.
25. Bamba H., Kondo Y., Wong R.M., Sekine S., Matsuzaki F. Minimum inhibitory concentration of various single agents and the effect of their combinations against Helicobacter pylori, as estimated by a fast and simple in vitro assay method. Am. J. Gastroenterol. 92:1997;659-662.
26. Kobayashi I., Hasegawa M., Saika T., Nishida M., Fujioka T., Nasu M. A new semisolid agar dilution method for determining amoxycillin, clarithromycin and azithromycin MICs for Helicobacter pylori isolates. J. Antimicrob. Chemother. 40:1997;713-716.
27. NCCLS. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 4th ed. Approved Standard. M7-A4, vol. 17. Vilanova PA, 1997.
28. Hartzen S.H., Andersen L.P., Bremmelgaard A. et al. Antimicrobial susceptibility of 230 Helicobacter pylori strains: importance of medium, inoculum and incubation time. Antimicrob. Agents Chemother. 41:1997;2634-2639.
29. Sjostron J.E., Larsson H. Factors affecting growth and antibiotic susceptibility of Helicobacter pylori: effect of pH and urea on the survival of a wild-type strain and a urease-deficient mutant. J. Med. Microbiol. 44:1996;425-433.
30. Xia H., Keane C.T., Beattie S., O'Morain C.A. Standardization of disk diffusion test and its clinical significance for susceptibility testing of metronidazole against Helicobacter pylori. Antimicrob. Agents Chemother. 38:1994;2357-2361.
31. Henriksen T.H., Brorson O., Schöyen R., Thoresen T., Lia A. A simple method for determining metronidazole resistance of Helicobacter pylori. J. Clin. Microbiol. 35:1997;1424-1426.
32. Haas C.E., Nix D.E., Schentag J.J. In vitro selection of resistant Helicobacter pylori. Antimicrob. Agents Chemother. 34:1990;1637-1641.
33. Sörberg M., Hanberger H., Nilsson M., Björkman A., Nilsson L.E. Risk of development of in vitro resistance to amoxicillin, clarithromycin and metronidazole in Helicobacter pylori. Antimicrob. Agents Chemother. 42:1998;1222-1228.
34. Debets-Ossenkopp Y.J., Sparrius M., Kusters J.G., Kolkman J.J., Vandenbroucke-Grauls C.M. Mechanism of clarithromycin resistance in clinical isolates of Helicobacter pylori. FEMS Microbiol. Lett. 142:1996;37-42.
35. Adamek R.J., Suerbaum S., Pfaffenbach B., Opferkuch W. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole and amoxicillin-influence on treatment outcome. Am. J. Gastroenterol. 93:1998;386-389.
36. Matsumoto S., Washizuka Y., Matsumoto Y. et al. Appearance of a metronidazoleresistant Helicobacter pylori strain in an infected-ICR-mouse model and difference in eradication of metronidazole resistant and sensitive strains. Antimicrob. Agents Chemother. 41:1997;2602-2605.
37. Penfold S.S., Lastovica A.J., Elisha B.G. Demonstration of plasmids in Campylobacter pylori. J. Infect. Dis. 157:1988;850-851.
38. Westblom T.U., Unge P. Drug resistance of Helicobacter pylori: memorandum from a meeting at the Sixth International Workshop on Campylobacter, Helicobacter and related organisms. J. Infect. Dis. 165:1992;974-975.
39. Wang Y., Roos K.P., Taylor D.E. Transformation of Helicobacter pylori by chromosomal metronidazole resistance and by a plasmid with a selectable chloramphenicol resistance marker. J. Gen. Microbiol. 139:1993;2485-2493.
40. Kuipers E.J., Israel D.A., Kusters J.G., Blaser M.J. Evidence for a conjugation-like nechanism of DNA transfer in Helicobacter pylori. J. Bacteriol. 180:1998;2901-2905.
41. Taylor D.E., Ge Z., Purych D., Lo T., Hiratsuka K. Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. Antimicrob. Agents Chemother. 41:1997;2621-2628.
42. Versalovic J., Shortridge D., Kibler K. et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob. Agents Chemother. 40:1996;477-480.
43. Versalovic J., Osato M.S., Spakovsky K. et al. Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. J. Antimicrob. Chemother. 40:1997;283-286.
44. Domingo D., Alarcón T., Sanz J.C., Sánchez I., López-Brea M. High frequency of mutations at position 2144 of the 23S rRNA gene in clarithromycin-resistant Helicobacter pylori strains isolated in Spain. J. Antimicrob. Chemother. 41:1998;573-574.
45. Hoffman P.S., Goodwin A., Johnsen J., Magee K., Veldhuyzen van Zanten S.J. Metabolic activities of metronidazole-sensitive and-resistant strains of Helicobacter pylori: repression of pyruvate oxidoreductase and expression of isocitrate lyase activity correlate with resistance. J. Bacteriol. 178:1996;4822-4829.
46. Lacey S.L., Moss S.F., Taylor G.W. Metronidazole uptake by sensitive and resistant isolates of Helicobacter pylori. J. Antimicrob. Chemother. 32:1993;393-400.
47. Reysset G. Genetics of 5-nitroimidazole resistance in Bacteroides species. Anaerobe. 2:1996;59-69.
48. Smith M.A., Edwards D.I. Oxygen scavenging, NADH oxidase and metronidazole resistance in Helicobacter pylori. J. Antimicrob. Chemother. 39:1997;347-353.
49. Goodwin A., Kersulyte D., Sisson G., Veldhuyzen van Zanten S.J., Berg D.E., Hoffman P.S. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase. Mol. Microbiol. 28:1998;383-393.
50. Debets-Ossenkopp Y.J., Goodwin A., Vandenbrouke-Grauls C.M.J.E., Pot R.G.J., Berg D.E., Hoffman P.S., Kusters J.G. IS605 insertion in the nitroreductase (rdxA) gene is responsible for metronidazole resistance in H. pylori NCTC 11638. Gut. 43(suppl. 2):1998;A1.
51. Midolo P.D., Korman M.G., Turnidge J.D., Lambert J.R. Helicobacter pylori resistance to tetracycline. Lancet. 347:1996;1194-1195.
52. Dore M.P., Realdi G., Mura I., Osato M.S., Graham D.Y., Sepulveda A.R. Amoxicillin resistant strains of Hp undergo reversible loss of resistance after storage. Gut. 41(suppl. 1):1997;A8.
53. Dore M.P., Graham D.Y., Sepulveda A.R. A novel penicillin-binding protein (PBP-D) is involved in amoxicillin resistance in Helicobacter pylori. Gut. 43(suppl. 2):1998;A7.
54. van Zwet AA, Kusters JG, Thij JC, van der Wouden EJ, Gerrits MM, Vandenbroucke-Grauls. Stable amoxicillin resistance in H. pylori: isolate from a patient repeatedly treated with antibiotics. Gut 1998;43(suppl 2):A6.
55. Moore R.A., Beckthold B., Wong S., Kureishi A., Bryan L.E. Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob. Agents Chemother. 39:1995;107-111.
56. Glupczynski Y. European Multicenter Study Group on antibiotic susceptibility of Helicobacter pylori. Results of a mulicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. Eur. J. Clin. Microbiol. Infect. Dis. 11:1992;777-781.
57. Ching C.K., Leung K.P., Yung R.W. et al. Prevalence of metronidazole resistant Helicobacter pylori strains among chinese peptic ulcer disease patients and normal controls in Hong Kong. Gut. 38:1996;675-678.
58. López-Brea M., Domingo D., Sánchez I., Alarcón T. Evolution of resistance to metronidazole and clarithromycin in Helicobacter pylori clinical isolated from Spain. J. Antimicrob. Chemother. 40:1997;279-281.
59. Noach L.A., Langenberg W.L., Bertola M.A., Dankert J., Tytgat G.N. Impact of metronidazole resistance on eradication of Helicobacter pylori. Scand. J. Infect. Dis. 26:1994;321-327.
60. Vasquez A., Valdez Y., Gilman R.H. et al. Metronidazole and clarithromycin resistance in Helicobacter pylori determined by measuring MICs of antimicrobial agents in color indicator egg yolk agar in a miniwell format. J. Clin. Microbiol. 34:1996;1232-1234.
61. Banatvala N., Davies G.R., Adbi Y. et al. High prevalence of Helicobacter pylori metronidazole resistance in migrants to east London: relation with previous nitroimidazole exposure and gastroduodenal disease. Gut. 35:1994;1562-1566.
62. Van der Wouden E.J., van Zwet A.A., Vosmaer G.D., Oom J.A., de Jong A., Kleibeuker J.H. Rapid increase in the prevalence of metronidazole resistant Helicobacter pylori in The Netherlands. Emerg. Infect. Dis. 3:1997;385-389.
63. López-Brea M., Martin E., López-Lavid C., Sanz J.C. Susceptibility of Helicobacter pylori to metronidazole. Eur. J. Clin. Microbiol. Infect. Dis. 10:1991;1082-1083.
64. Pires Y., Cabrita J., Morgado C., Vitor J., Silva T., Lopes T., Guerreiro S., Quina M. H. pylori isolation in dyspeptic patients in Lisbon: 1987-1991. Antimicrobial resistance and plasmid profile. Ital. J. Gastroenterol. 23(suppl. 2):1991;45-46.
65. Tucci A., Varoli O., Corinaldesi R., Stanghellini V., Gasperoni S., Paparo G.F., Ricci-Maccarini M., Laplaca M., Barbara L. Evaluation of H. pylori sensitivity to amoxycillin and metronidazole in dyspeptic patients. Ital. J. Gastroenterol. 25:1993;65-67.
66. Raymond J., Kalach N., Bergeret M., Benhamou P.H., Barbet J.P., Gendrel D., Dupont C. Effect of metronidazole resistance on bacterial eradication of Helicobacter pylori in infected children. Antimicrob. Agents Chemother. 42:1998;1334-1335.
67. Becx M.C., Janssen A.J., Clasener H.A., De Koning R.W. Metronidazole-resistant Helicobacter pylori. Lancet. i:1990;539-540.
68. Glupczynski Y., Burette A., De Koster E., Nyst J.F., Deltenre M., Cadranel S., Bourdeaux L., De Vos D. Metronidazole-resistance in Helicobacter pylori. Lancet. i:1990;976-977.
69. Rautelin H., Seppala K., Renkonen O., Vainio U., Kosunen T. Role of metronidazole resistance in therapy of H. pylori infections. Antimicrob. Agents Chemother. 36:1992;163-166.
70. Glupczyuski Y. Antimicrobial resistance in Helicobacter pylori: a global overview. Hunt R.H., Tytgat G.N.J. Helicobacter pylori. Basic mechanims to clinical cure 1998. 1998;398-415 Kluwer, Dordrecht.
71. Goodwin C.S., Marshall B.J., Blincow E.D., Wilson D.H., Blackbourn S., Phillips M. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. J. Clin. Pathol. 41:1988;207.
72. Parasakthi N., Goh K.L. Primary and acquired resistance to clarithromycin among Helicobacter pylori strains in Malaysia. Am. J. Gastroenterol. 90:1995;519.
73. López-Brea M., Martin E., Sanz J.C., Moreno M.J., Martinez M.J., Alarcón T. In vitro susceptibility of H. pylori Spanish clinical isolates to clarithromycin. Acta Gastroentrol. Belg. 56(suppl.):1993;126.
74. Glupczynski Y., Goutier S.S., van der Borre C., Butzler J.P., Burette A. Surveillance of Helicobacter pylori resistance to antimicrobial agents in Belgium from 1989 to 1994. Gut. 37(suppl. 1):1995;A56.
75. Rozynek E., Dziernanowsak D., Celinska-Cedro D., Jeljaszewicz J. Primary resistance to metronidazole and other antibiotics of Helicobacter pylori isolated from children in Poland. Eur. J. Clin. Microbiol. Infect. Dis. 16:1997;943-944.
76. Lerang F., Moum B., Haug J.B. et al. Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease does in vitro metronidazole resistance have any clinical relevance? Am. J. Gastroenterol. 92:1997;248-253.
77. Van der Hulst R.W., van der Ende A., Homan A., Roorda P., Dankert J., Tytgat G.N.J. Influence of metronidazole resistance on efficacy of quadruple therapy for Helicobacter pylori eradication. Gut. 42:1998;166-169.
78. Logan R.P.H., Gummett P.A., Misiewicz J.J., Karim Q.N.N., Walker M.M., Baron J.H. One week eradication regimen for Helicobacter pylori. Lancet. 338:1991;1249-1252.
79. Burette A., Glupczynski Y., DePrez C. Evaluation of various multi-drug eradication regimens for Helicobacter pylori. Eur. J. Gastroenterol. Hepatol. 4:1992;817-823.
80. Lerang F., Moum B., Ragnhildsveit E. et al. Simplified ten days triple therapy for cure of Helicobacter pylori infection. Gastroenterology. 112:1997;A198.
81. Thijs J.C., van Zwet A.A., Thijs W.J., van der Wouden E.J., Kooy A. One-week triple therapy with omeprazole, amoxicillin and tinidazole for Helicobacter pylori infection: the signnificance of imidazole resistance. Aliment. Pharmacol. Ther. 11:1997;305-309.
82. Miyaji H, Ito S, Azuma et al. The prevalence of the drug resistance in Helicobacter pylori and the effects of the resistance on eradication therapy in Japan. Gastroenterol 1997;112:A222.
83. Harris A.W., Pryce D.I., Gabe S.M. et al. Lansoprazole, clarithromycin annd metronidazole for seven days in Helicobacter pylori infection. Aliment. Pharmacol. Ther. 10:1996;1005-1008.
84. Moayyedi P., Chalmers D.M., Axon A.T. Patient factors that predict failure of omeprazole, clarithromycin and tinidazole to eradicate Helicobacter pylori. J. Gastroenterol. 32:1997;24-27.
85. DeCross A.J., Marshall B.J., McCallum R.W., Hoffman S.R., Barrett L.J., Guerrant R.L. Metronidazole susceptibility testing for Helicobacter pylori comparison of disk, broth and agar dilution methods and their clinical relevance. J. Clin. Microbiol. 31:1993;1971-1974.
86. Peitz U., Nusch A., Tillenburg B., Stolte M., Borsch G., Labenz J. High cure rate of H pylori infection by one week therapy with omeprazole (ome), metronidazole (met) and clarithromycin (cla) despite a negative impact by met resistance. Gut. 39(suppl. 2):1996;A5.
87. Graham D.Y., Hoffman J., El-Zimaity H.M.T., Graham D.P., Osato M. Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 11:1997;935-938.
88. Cayla R., Zerbib F., Talbi P., Megraud F., Lamouliatte H. Pre and post treatment clarithromycin resistance of Helicobacter pylori strains: a key factor of treatment failure. Gut. 37(suppl. 1):1995;A55.
89. Schütze K., Hentschel E., Hirschl A.M. Clarithromycin or amoxicillin plus high dose ranitidine in the treatment of Helicobacter pylori positive functional dyspepsia. Eur. J. Gastroenterol. Hepatol. 8:1996;41-46.
90. Wurzer H., Rodrigo L., Stamler D. et al. Short course therapy with amoxicillinclarithromycin triple for 10 days (ACT-10) eradicates H. pylori and heals duodenal ulcer. Aliment. Pharmacol. Ther. 11:1998;943-952.
91. Lamouliatte H., Cayla R., Zerbib F., Talbi P., Megraud F., de Mascarel A. Triple therapy with PPI-amoxicillin-clarithromycin for H. pylori eradication: the optimal regimenn in 1996. Gastroenterology. 110:1996;A171.
92. Burette A., Lamy V., Ramdani B., Cappelli J., DePrez C., Glupczynski Y. Lansoprazole (30mgOD vs BID) with amoxicillin and clarithromycin to cure Helicobacter pylori infection. Gut. 39(suppl. 2):1996;A33.
93. Buckley M.J.M., Xia H.X., Hyde D.M., Keane C.T., O'Morain C.A. Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance. Dig. Dis. Sci. 42:1997;2111-2115.